


Product Name : AD1058
Cat. No. : PC-22828
CAS No. : 2907782-78-7
Molecular Formula : C₁₉H₂₀N₆O₃S
Molecular Weight : 412.47
Target : ATM/ATR
Solubility : 10 mM in DMSO



CAS: 2907782-78-7

Biological Activity

AD1058 is a highly potent, selective, brain-penetrant **ATR** inhibitor with IC₅₀ of 1.6 nM.

AD1058 displays excellent selectivity against 15 kinases belonging to six kinase subfamilies (mTOR from PIKK subfamily; AMPKα2β1γ1, DRAK2, BRSK2, ARK5 from CAMK subfamily; CDK2 from CMGC subfamily; IRAK4 from TKL subfamily; FLT3, LCK, MER, LYN, BTK, ABL1, JAK1 from TK subfamily; Aurora B from Aurora subfamily).

AD1058 exhibits potent in vitro antiproliferative activities against a panel of tumor cell lines (B-cell lymphoma: Granta-519 (IC₅₀=0.19 μM), OCI-Ly10, SU-DHL4, ovary cancer: A2780, colorectal cancer: LoVo, HCT116, HT-29, DLD1, lung cancer: NCI-H446, pancreatic cancer: Capan-1, and prostate cancer: PC-3).

AD1058 effectively inhibits Niraparib-induced CHK1 phosphorylation in Granta-519, more potently than AZ20 or AZD6738 at 2 μM. AD1058 (25 and/or 50 mg/kg) exhibits significant inhibition of tumor growth in CB17-SCID mice bearing xenograft tumor inoculating Granta-519, effectively improves the antitumor effect of the clinically ionizing radiotherapy.

References

Liu Z, et al. *J Med Chem*. 2024 Jul 25. doi: 10.1021/acs.jmedchem.4c00734.

Caution: Product has not been fully validated for medical applications. Lab Use Only!

E-mail: tech@probechem.com